Indeed, the clinical behavior (including tumor kinetics and sites of recurrence) of ER-positive/HER2 positive subtype (HER2-positive luminal B breast cancer) differs from that of ER-negative HER2 enriched subtype [55–58]. This evidence concerns the gene ESR1 and breast cancer.